Viral Vector Upstream Platforms
Gene therapies use viral vectors to introduce modified genetic material into cells. Our optimized upstream platforms address key challenges in viral vector production, including upstream processing productivity, product quality, process robustness, and scalability for commercial manufacturing, allowing you to accelerate the development of your viral vector-based therapies. With our technical and regulatory expert support, you can navigate the complexities of viral vector production efficiently.
Discover how our new AAViator™ Production Platform can improve upstream yield and productivity, speeding up your development timelines. Download the whitepaper “Streamline your AAV Process with the AAViator™ Production Platform".
New AAViator™ Production Platform
Performance in Small-scale Culture Systems and Bench-scale Bioreactors
The AAViator™ Production Platform delivers robust adeno-associated virus (AAV) vector production by integrating our innovative transfection system and chemically defined cell culture medium. The platform streamlines process development and vector production, allowing gene therapy developers to accelerate timelines while maintaining high product quality.
Key Benefits
- A complete, ready-to-use, solution for robust transient AAV production in HEK293 cells
- Proven performance and versatility across multiple AAV serotypes, HEK cell lines, transgene sizes, and production scales.
- Accelerates upstream process development reducing the need for extensive transfection reagent or media optimization
Learn more about our AAViator™ Production Platform. You will be directed offsite to MirusBio.com.
Products
Our upstream platforms pair a cell line and cell culture medium, optimized for productivity. Although optimized to work together, each cell line and cell culture medium can be used independently. The platforms are supported with detailed protocols developed by our technical experts to achieve optimal performance, saving you time in process development and speeding delivery of your therapy to patients.
Key Benefits of Our Cell Lines
- GMP-banked, fully characterized and tested for adventitious agents
- Licenses available for research or clinical/commercial use
- Fully traceable and with documentation for regulatory filings
Key Benefits of Our Cell Culture Media
- Chemically defined, animal component-free
- GMP compliant manufacturing
- Available in liquid and dry powder formats
THE VIRUSEXPRESS® LENTIVIRAL PLATFORM
For Saving Time in Process Development of Lentiviral Vector-Based Cell Therapies.
The VirusExpress® Lentiviral Platform is a transfection-based solution to lentiviral production challenges and offers a scalable upstream process optimized for suspension-based lentivirus production.
Key Benefits of HEK293T VirusExpress® Cells
- Cell line grows to high cell density and viability in suspension and has low doubling time
- Selected for higher lentivirus production using PEI-based transient transfection method
- GMP-banked, fully characterized and adventitious agent tested
- Licenses available for research or clinical/commercial use.
- Fully traceable and documentation available for regulatory filings
Key Benefits of EX-CELL® CD HEK293 Viral Vector Medium
- Supports high cell density and faster growth of HEK293T cells
- Compatible with the PEI based transfection reagents used for viral production
- Eliminates need for transfection step boost and enhancer reagents
- Chemically defined, animal component-free
- GMP compliant manufacturing
- Available in liquid and dry powder formats
THE VIRUSEXPRESS® AAV PLATFORM
For Saving Time in Process Development of HEK293 Cells Based Gene Therapies.
The VirusExpress® AAV Platform offers a transfection-based solution to AAV production challenges, and an upstream process optimized for scalable, suspension-based AAV production.
Key Benefits of HEK293 VirusExpress® Cells
- Cell line grows to high cell density and viability in suspension and has low doubling time
- Selected for higher AAV production using PEI-based transient transfection method
- GMP-banked, fully characterized and adventitious agent tested
- Licenses available for research or clinical/commercial use
- Fully traceable and documentation available for regulatory filings
Key Benefits of Cellvento® 4HEK Medium
- Maximizes viable cell density and AAV productivity
- Supports growth of multiple HEK293 cell lines with diverse nutritional requirements
- Compatible with the PEI based transfection reagents used for AAV production
- Chemically defined, animal component-free cell culture medium
- GMP compliant manufacturing
- Available in liquid and dry powder formats
THE Sf-RVN® PLATFORM
For Improving the Safety Profile of Your Insect Cell Based Gene Therapies.
Insect cell expression systems are an appealing alternative for AAV production as they are easy to cultivate and do not rely on transfection. However, as many Sf-9 insect cell lines are contaminated with Sf-Rhabdovirus, the Sf-Rhabdovirus negative Sf-9 cell line (Sf-RVN®) offers an improved viral safety profile and is an attractive option for scalable AAV production.
The Sf-RVN® Platform includes a Sf-Rhabdovirus-free cell line with enhanced risk mitigation, and provides a high-performance, scalable platform optimized for AAV production.
Key Benefits of Sf-RVN® Insect Cell Line
- A proven Sf-Rhabdovirus-negative Sf-9 cell line
- Same characteristics as Sf-9 cells
- GMP-banked, fully characterized and adventitious agent tested
- Licenses available for research or clinical/commercial use
- Fully traceable and documentation available for regulatory filings
Key Benefits of EX-CELL® CD Insect Cell Medium
- Optimized for growth and productivity of Sf-9 cells
- Supports growth of multiple insect cell lines (Sf-21, S2, Tni and C636)
- Chemically defined and animal component free
- GMP compliant manufacturing
- Available in liquid and dry powdered medium
The Sf-RVN® Platform Performance for Growth and AAV Production
Related Resources
- Article: Scalability Challenges of Viral Vector Manufacturing
Scaling up viral vector production using adherent cell culture systems is challenging. Learn how suspension cell culture systems benefit large-scale bioprocessing.
- Article: Bioreactor Process Development and Scale-Up for Transient Transfection-Based Lentivirus Manufacturing in Suspension Cell Culture
A step-by-step overview of suspension-based, transient transfection bioreactor process development and scaleup of lentivirus production.
- Article: Bioprocessing And Scale-Up Of Suspension HEK293 Cells For AAV Manufacturing
To address scalability challenges of AAV manufacturing, we developed an HEK293 suspension cell line that can be used across many serotypes. Get the data in this article.
- Article: Development of a Novel Sf9 Rhabdovirus-Negative Cell Line (Sf-RVN®) and Companion Chemically Defined Medium
See how the Sf9 rhabdovirus-free cell line was developed and how we’ve developed a companion chemically-defined insect cell media for protein and viral expression.
- Article: Development of a Novel Cell Culture Medium for AAV Production With Multiple HEK293 Lineages and Process Optimization
Read our white paper on the development of a novel cell culture medium for AAV production with multiple HEK293 lineages and process optimization.
Related Videos
Related Webinars
To continue reading please sign in or create an account.
Don't Have An Account?